Mechanism of action
The action occurs as the drug potentiates the effect of levodopa by decreasing the metabolism of dopamine. It is an inhibitor of monoamine oxidase enzyme (MAO-B) in brain.
Medical Articles
Selegiline, a monoamine oxidase (MAO) inhibitor, is approved by the U.S. Food and Drug Administration (FDA) as an adjunct treatment for patients with Parkinson disease and a major depressive disorder in adults.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.